Medical Radiology and Radiation Safety. 2026. Vol. 71. № 1
DOI:10.33266/1024-6177-2026-71-1-33-38
O.D. Bragina1,2, A.G. Ivanova1, M.S. Larkina2, 3, R.N. Varvashenya2, 3,
M.A. Vostrikova1, N.O. Popova1, V.E. Goldberg1, V.I. Chernov1, 2, S.V. Patalyak1
Evaluation of the Safety and Pharmacokinetic Analysis
of the Radiopharmaceutical [99mTc]Tc-DB8 in Breast Cancer Patients
1 Tomsk National Research Medical Center, Tomsk, Russia
2 National Research Tomsk Polytechnic University, Tomsk, Russia
3 Siberian State Medical University, Tomsk, Russia
Contact person: A.G. Ivanova, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To evaluate the safety and pharmacokinetics of the radiopharmaceutical agent [99mTc]Tc-DB8 in patients with breast cancer.
Material and methods: The study included 15 patients diagnosed with breast cancer (T2‒4 N0‒3 M0‒1) prior to any systemic or local treatment. Patients were divided into three groups based on the administered protein dose: 40 µg, 80 µg, and 120 µg (5 patients per group). Throughout the study, participants were under continuous clinical observation, which included assessment of symptoms, measurement of blood pressure (BP), body temperature, and heart rate prior to injection, and at 2, 4, 6, 24, and 48 hours post-injection. Additionally, complete blood count, biochemical blood analysis, and electrocardiography were performed before the injection, and again at 24 and 48 hours post-administration.
To assess the elimination rate of [99mTc]Tc-DB8 from the bloodstream, its distribution in organs and tissues, and the associated radiation dose, whole-body planar scintigraphy was conducted at 2, 4, 6, and 24 hours after radiopharmaceutical administration at doses of 40, 80, and 120 µg. The average administered activity was 334 ± 84 MBq, with a radiochemical purity exceeding 95 %.
Results: Injection of [99mTc]Tc-DB8 was not associated with any reported complaints or clinically significant changes in blood pressure, heart rate, or body temperature at any of the time points, regardless of dose. No significant deviations were observed in complete blood count, biochemical parameters, urinalysis, or ECG prior to injection, or at 48 hours and 7 days post-administration. The elimination half-life was 2.363 h for the 40 µg and 80 µg doses, and 2.233 h for the 120 µg dose. The highest absorbed doses were recorded in the mammary glands, kidneys, adrenal glands, pancreas, thyroid gland, urinary bladder and ovaries. The effective dose was 0.009 ± 0.001 mSv/MBq for the 40 µg dose, 0.011 ± 0.004 mSv/MBq for the 80 µg dose, and 0.014 ± 0.003 mSv/MBq for the 120 µg dose.
Conclusion: The drug is safe at all stages of dynamic follow-up, which is confirmed by the subjective feelings of breast cancer patients and the absence of pathological changes according to laboratory and instrumental studies, which allows the continuation of the next stages of clinical trials. Similarly, [99mTc]Tc-DB8 demonstrated rapid elimination from the bloodstream when using 40, 80 and 120 micrograms of protein, and the highest absorption was recorded in the mammary gland, kidneys, adrenal glands, pancreas, thyroid, bladder and ovaries. Based on the results of the completed analysis, the use of the drug [99mTc]Tc-DB8 served as the basis for further studies.
Keywords: target radionuclide diagnostics, luminal breast cancer, 99mTc-DB-8
For citation: Bragina OD, Ivanova AG, Larkina MS, Varvashenya RN,Vostrikova MA, Popova NO, Goldberg VE, Chernov VI, Patalyak SV. Evaluation of the Safety and Pharmacokinetic Analysis of the Radiopharmaceutical [99mTc]Tc-DB8 in Breast Cancer Patients. Medical Radiology and Radiation Safety. 2026;71(1):33–38. (In Russian). DOI:10.33266/1024-6177-2026-71-1-33-38
References
1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics. CA Cancer J Clin. 2022;72;1:7–33. Doi: 10.3322/caac.21708.
2. Kay C., Martinez-Perez C., Dixon J.M., Turnbull A.K. The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer. J Pers Med. 2023;13;10:1476. Doi: 10.3390/jpm13101476.
3. Verheuvel N.C., van den Hoven I., Ooms H.W.A, Voogd A.C., Roumen R.M.H. The Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging Of Invasive Breast Cancer in the Post-ACOSOG Z0011 Trial Era. Ann Surg Oncol. 2014;21:409–415. Doi: 10.1245/s10434-014-4071-1.
4. Keelan S., Heeney A., Downey E., Hegarty A., Roche T., Power C., et al. Breast Cancer Patients with a Negative Axillary Ultrasound may have Clinically Significant Nodal Metastasis. Breast Cancer Res Treat. 2021;187;2:303–310. Doi: 10.1007/s10549-021-06194-8.
5. Aurilio G., Disalvatore D., Pruneri G., Bagnardi V., Viale G., Curigliano G., et al. A Meta-Analysis of Oestrogen Receptor, Progesterone Receptor and HER2 Discordance between Primary Breast Cancer and Metastases. Eur J Cancer. 2014;50;2):277–289. Doi: 10.1016/j.ejca.2013.10.004.
6. Schrijver W.A.M.E., Suijkerbuijk K.P.M., van Gils C.H., van der Wall E., Moelans C.B., van Diest P.J. Receptor Conversion in Distant Breast Cancer Metastases: a Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2018;110;6:568–580. Doi: 10.1093/jnci/djx273.
7. Pan H., Gray R., Braybrooke J., Davies C., Taylor C., McGale P., et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377;19:1836–1846. Doi: 10.1056/NEJMoa1701830.
8. Yuan J., Yang L., Li Z., Zhang H., Wang Q., Huang J., et al. The Role of the Tumor Microenvironment in Endocrine Therapy Resistance in Hormone Receptor-Positive Breast Cancer. Front Endocrinol. 2023;14:1261283. Doi: 10.3389/fendo.2023.1261283.
9. D’Onofrio A., Engelbrecht S., Läppchen T., Rominger A., Gourni E. GRPR-Targeting Radiotheranostics for Breast Cancer Management. Front Med. 2023;10:1250799. Doi: 10.3389/fmed.2023.1250799.
10. Брагина О.Д., Иванова А.Г., Усынин Е.А. Радионуклидная визуализация GRPR при злокачественной патологии молочной и предстательной желез: опыт клинического применения // Бюллетень сибирской медицины. 2025. Т.24. №1. С. 164–172. [Bragina O.D., Ivanova A.G., Usynin Ye.A.. Radionuclide Visualization of GRPR in Malignant Pathology of the Mammary and Prostate Glands: Experience of Clinical Application. Byulleten’ Sibirskoy Meditsiny = Bulletin of Siberian Medicine. 2025;24;1:164–172 (In Russ.)]. Doi: 10.20538/1682-0363-2025-1-164-172.
11. Брагина О.Д., Деев С.М., Чернов В.И., Толмачев В.М. Эволюция таргетной радионуклидной диагностики HER2-позитивного рака молочной железы // Acta Naturae. 2022. Т.14. №2. С. 4–15 [Bragina O.D., Deyev S.M., Chernov V.I., Tolmachev V.M. Evolution of Targeted Radionuclide Imaging for HER2-Positive Breast Cancer. Acta Naturae. 2022;14;2:4–15 (In Russ.)]. Doi: 10.32607/actanaturae.11611.
12. Bragina O.D., Tashireva L.A., Loos D.M., Chernov V.I., Hober S., Tolmachev V.M. Evaluation of Approaches for the Assessment of HER2 Expression in Breast Cancer by Radionuclide Imaging Using the Scaffold Protein [99mTc]Tc-ADAPT6. Pharmaceutics. 2024;16;4:445. Doi: 10.3390/pharmaceutics16040445.
13. D’Onofrio A., Silva F., Gano L., Raposinho P., Fernandes C., Sikora A., et al. Bioorthogonal Chemistry Approach for the Theranostics of GRPR-Expressing Cancers. Pharmaceutics. 2022;14;12:2569. Doi: 10.3390/pharmaceutics14122569.
14. Vorster M., Hadebe B.P., Sathekge M.M. Theranostics in Breast Cancer. Front Nucl Med. 2023;3:1236565. Doi: 10.3389/fnume.2023.1236565.
15. Chernov V., Rybina A., Zelchan R., Medvedeva A., Bragina O., Lushnikova N., et al. Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors. Cancers. 2023;15;6:1631. Doi: 10.3390/cancers15061631.
16. Bragina O., Chernov V., Larkina M., Rybina A., Zelchan R., Garbukov E., et al. Phase I Clinical Evaluation of 99mTc-labeled Affibody Molecule for Imaging HER2 Expression in Breast Cancer. Theranostics 2023;13;14:4858-4871. Doi: 10.7150/thno.86770.
17. Брагина О.Д., Чернов В.И., Гарбуков Е.Ю., Дорошенко А.В., Воробьева А.Г., Орлова А.М. и др. Возможности радионуклидной диагностики Her2-позитивного рака молочной железы с использованием меченных технецием-99m таргетных молекул: первый опыт клинического применения // Бюллетень сибирской медицины. 2021. Т.20. №1.
С. 23-30. [Bragina O.D., Chernov V.I., Garbukov Ye.Yu., Doroshenko A.V., Vorob’yeva A.G., Orlova A.M., et al. Possibilities of Radionuclide Diagnostics of Her2-Positive Breast Cancer using Technetium-99m-Labeled Target Molecules: First Experience of Clinical Application. Byulleten’ Sibirskoy Meditsiny = Bulletin of Siberian Medicine. 2021;20;1:23-30 (In Russ.)]. Doi: 10.20538/1682-0363-2021-1-23-30.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was carried out within the framework of the Russian Science Foundation grant No. 22-15-00169 on the topic “Phenotype of BRCA-like tumors in the process of carcinogenesis and treatment”.
Contribution. O.D. Bragina – development of the study concept and design, data analysis and interpretation, discussion of the manuscript, and checking the critical intellectual content. A.G. Ivanova – data analysis and interpretation, discussion of the manuscript, and checking the critical intellectual content. M.S. Larkina ‒ data analysis and interpretation, discussion of the manuscript, and checking the critical intellectual content. R.N. Varvashenya – data analysis and interpretation, discussion of the manuscript, and checking the critical intellectual content. M.A. Vostrikova – data collection and processing. N.O. Popova ‒ data collection and processing. V.E. Goldberg ‒ data collection and processing. V.I. Chernov – development of the study concept and design, data analysis and interpretation, discussion of the manuscript, and checking the critical intellectual content. S.V. Patalyak ‒ data collection and processing.
Article received: 20.11.2025. Accepted for publication: 25.12.2025.